**Some Personal News**
THE TEN YEAR WAR, my new book, is available for pre-order.
It’s an effort to tell the story of Obamacare and, more broadly, the story of American politics over the last decade. (1)
https://t.co/xFYluV7iTE
It is striking that it doesn't occur to this person that a 68-year-old man who has made a lot of money might care about his integrity far more than about his next paycheck. Maybe at that age you decide working for Temu Fox News just isn't worth it and hang it up!
Earlier today, @DrOzCMS claimed that large numbers of Marketplace enrollees aren’t “legit” on the grounds that some enrollees don't file a claim in any given year. Re-upping this thread on why this argument is seriously flawed.
"We should be clear: Bari Weiss is murdering 60 Minutes. She is doing so not out of incompetence or foolishness, but with malice aforethought. She is doing it at the behest of her corporate patron."
https://t.co/ptjRbzqB0k
There is some really huge news in the fight against cancer.
@ZekeEmanuel talked to @CitizenCohn about this breakthrough — and how Trump’s war on research puts future discoveries at risk.
NEW at @BulwarkOnline
Donald Trump is dismantling America's medical innovation machine by
- cutting research funds
- politicizing grants
- purging gov't scientists
And this weeks big cancer breakthrough shows just how much we stand to lose https://t.co/lNzysKd3pD
I would absolutely not count McMorrow out yet. Still a long way to go and the deleted tweets are mostly old news at this point. She had a good showing at the Mackinac debate and still has legs in this race, especially if Stevens continues to get hammered on AIPAC.
At the world’s largest cancer research meeting, data briefly took a backseat to grief.
At every annual meeting of the American Society of Clinical Oncology, the congregation of oncologists scrutinizes data on survival and mortality. But comparatively few conversations focus on the loss that is inherent in the work of cancer doctors. That changed a bit this year.
In his opening address, the organization’s outgoing president, Eric Small, spoke about his partner, University of California, San Francisco, oncologist Amy Lin, who passed away in December. She had metastatic clear cell ovarian cancer, a rare disease with few treatment options. Small also brought a different kind of specialist to ASCO’s mainstage: David Kessler, an expert on grief and loss, who gave a talk about compassionate end-of-life care.
Read this moving story by @kathmacphail.
https://t.co/TcOkuLplld
A new cancer drug works like a molecular handcuff. One arm grabs a passing immune cell. The other grabs the tumor. It clamps them together and forces the kill, whether the cancer agrees to the meeting or not.
That trick cleared blood cancers a decade ago. Blinatumomab still does it in leukemia.
Solid tumors blocked it for one reason: the old handcuffs could only grab a protein sitting on the cell’s surface, and solid tumors hide their tells inside the cell.
This one reads the inside. Its grabbing arm is built from a T-cell receptor, so it spots the scraps of internal proteins that every cell puts on display. In a phase 1 study, 61 patients, it shrank head and neck, melanoma, and lung tumors that surface-only drugs never reached.
Solid tumors are most cancer. This is the first handcuff that fits them.
Voter reaction I'm hearing so far in Maine feels different than Reddit/tattoo. Supporters were quick to brush those off, but this is raising doubts about whether he really is reformed, even among people who still plan to vote for him. "I feel sickened that I have vote for him."
“Dozens of measles patients have been hospitalized with serious symptoms such as brain inflammation or pneumonia, he said, and one baby developed life-threatening congenital measles during pregnancy but survived.” https://t.co/Nei5m4G3zc
People who don't follow cancer research often ask me why we haven't cured cancer. That perception masks a wonderful reality: We make amazing, stepwise progress every year, and the result is that many people live much longer today than they would have previously.
Right now we're in the thick of the annual meeting of the American Society of Clinical Oncology, the biggest research meeting on new cancer medicines, and this morning a bunch of really important studies dropped. I'm going to review them here.
This first image is the result for daraxonrasib, a treatment for pancreatic cancer that is generating consdirable excitement. The green line is the probability of living for patients who got the new drug; the gray one is the chemo control group.
If you follow cancer drugs, a chart like this will make your breath hitch a little. I'm going to review these and some other data here.
One of the most meaningful moments in any #Ebola response is seeing survivors recover and receive their survivor certificates.
Having cared for Ebola patients during the West Africa outbreak, I still remember filling out and presenting these certificates. They represent far more than recovery from a virus—they symbolize resilience, hope, and the collective efforts of healthcare workers, families, and communities.
It is wonderful to see these frontline responders recover and to see @DrTedros, @WHO and @AfricaCDC leadership present to recognize this important milestone.
Congratulations to the survivors, and thank you to everyone involved in their care. Moments like these remind us why this work matters.
In #Ebola outbreaks, communities can distrust treatment centers, because loved ones go in & often don't come out alive. Hopefully word of survivals will encourage people to seek care rather than staying home. Improves their survival chances & lowers risk to family members.
“The reality is, you get them out as quickly as possible or you’re not going to be able to get them out at all."
@CitizenCohn talks to Ebola specialists who are aghast at Trump's plan for the outbreak https://t.co/RGb5xWJ3TU
Medicaid work requirements are projected to cause many workers to lose eligibility due to weekly fluctuations in the number of hours worked
New research by Paul Shafer, @THCallaghan, @bjdickmayhew at #ARM26